| |
Newsroom /
Medical
/
Medical
/
Antifungals Market to 2016
Antifungals Market to 2016
The Antifungals Market is Forecast To Grow At Moderate Rate From 2009 to 2016
London,
London,
United Kingdom
(prbd.net)
02/02/2011
GBI research forecasts the global antifungals market to grow at a rate of 1.9% annually for the next seven years to reach $8.4 billion by 2016. It was valued at $7.4 billion in 2009. This moderate growth will primarily be supported by an increase in the treatment seeking and the diagnosed rates during the forecast period. The growth of the antifungals market during the forecast period will not be much lower than the rate at which it grew between 2001 and 2009. This is primarily attributed to two reasons: firstly, the antifungals market is dominated by generic products which generate less revenue per unit sold; secondly, the pipeline for the antifungals market is weak with a small number of molecules across different stages of development. However, the continued uptake of the currently marketed products and the launch of some of the late-stage pipeline molecules will sustain market growth during the forecast period.
For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Antifungals-Market-to-2016-Promising-Antifungals-in-Pipeline-Includes-Novel-Azoles-Polyenes-and-Echinocandin&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
The Introduction of Posconazole (Noxafil) for the treatment of invasive aspergillosis has been significant in reducing the mortality rates of the infected patients. Noxafil is considered to be more effective with fewer side effects, and its cost of treatment is lower than the earlier treatments. Based on these factors, the percentage of the population being treated for invasive aspergillosis is increasing.
Dermatophytosis is a fungal infection that causes rashes and visible marks and itching on the skin. Fungal infections are common in the obese and diabetic populations. As the total diabetic population is increasing, GBI Research expects more infected patients will seek treatment.
GBI Research, a leading business intelligence provider, has released its latest research Antifungals Market to 2016 - Promising Antifungals in Pipeline Includes Novel Azoles, Polyenes and Echinocandin”, which provides insights on antifungals sales and price forecasts until 2016. The report also examines global treatment usage patterns of antifungal therapies. The geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report includes insights into the antifungal Research and Development (R&D) pipeline and potential future blockbusters up to 2016. The report provides an in-depth analysis of the top three antifungal therapeutic indications, which are aspergillosis, dermatophytosis and candidiasis. It also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report explores the competitive landscape including top companies benchmarking and the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving antifungals therapies are also presented.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Antifungals-Market-to-2016-Promising-Antifungals-in-Pipeline-Includes-Novel-Azoles-Polyenes-and-Echinocandin&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|